Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

Fig. 1

CONSORT diagram. The flow diagram shows the intention-to-treat population of 147 patients included in the primary analysis of bevacizumab plus paclitaxel (arm A) compared with bevacizumab plus metronomic chemotherapy (arm B). Bev=bevacizumab; PD=progressive disease

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us